Harvard Bioscience (HBIO) 6.22 $HBIO Shares of HBIO Up

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Harvard Bioscience (HBIO) 6.22 $HBIO

Shares of HBIO Up 31.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Apr 24, 9:24AM CDT
SmarTrend identified an Uptrend for Harvard Bioscience (NASDAQ:HBIO) on October 21st, 2014 at $4.69. In approximately 6 months, Harvard Bioscience has returned 31.34% as of today's recent price of $6.16.
HBIO: 6.22 (+0.08)

Next Week In Biotech: Gilead, Celgene Report; PDUFAs For Theravance, The Medicines Co.
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 24, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
VRX: 210.42 (+1.03), BMRN: 120.28 (-2.67), UTHR: 186.69 (-1.87), CLDX: 30.10 (+0.19), ACOR: 33.12 (-0.38), AFFX: 12.44 (-0.16), HSP: 87.61 (-0.05), OXGN: 1.48 (unch), MACK: 13.42 (-0.25), HBIO: 6.22 (+0.08), ECYT: 6.17 (-0.13), GEVA: 108.51 (+0.92), CYTR: 5.13 (-0.13), THRX: 17.92 (+0.46), FF: 11.18 (+0.03), MDXG: 9.81 (-0.39), EXEL: 3.08 (-0.02), VRTX: 133.20 (-2.62), NEO: 4.75 (-0.11), PFE: 35.27 (-0.09), INCY: 107.34 (-0.51), MYL: 76.06 (+2.37), AMGN: 167.91 (-1.26), ANIK: 38.35 (-0.32), ALKS: 62.26 (-1.19), ONTY: 1.74 (-0.05), CELG: 118.71 (+2.62), NBIX: 43.37 (-0.31), SGEN: 37.14 (-0.36), OGXI: 2.19 (+0.04), EBIO: 11.19 (+0.69), ABAX: 63.62 (+0.31), GILD: 103.69 (-1.52), GERN: 4.30 (-0.03), HAE: 43.35 (+0.74), MRK: 57.60 (+0.09), TEVA: 64.41 (+1.16), PCRX: 85.07 (+0.80)

Harvard Bioscience Schedules First Quarter 2015 Conference Call for April 30 at 11:00 AM ET
GlobeNewswire - Tue Apr 21, 3:05PM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its first quarter 2015 before market trading hours on Thursday, April 30, 2015. A conference call to discuss the company's first quarter 2015 financial results and its operations is scheduled for that same date at 11:00 AM ET. On that call, management may respond to questions from the audience and provide information on any of a number of topics related to the business, including operations, plans and outlook.
HBIO: 6.22 (+0.08)

Harvard Bioscience Shares Up 40.9% Since SmarTrend's Buy Recommendation (HBIO)
Comtex SmarTrend(R) - Thu Apr 16, 4:50PM CDT
SmarTrend identified an Uptrend for Harvard Bioscience (NASDAQ:HBIO) on October 21st, 2014 at $4.69. In approximately 6 months, Harvard Bioscience has returned 40.94% as of today's recent price of $6.61.
HBIO: 6.22 (+0.08)

The Best Small Cap Stocks To Buy Now
Todd Campbell - at Seeking Alpha - Mon Apr 06, 4:40AM CDT

PMC: 30.50 (-0.29), MATW: 50.80 (-0.20), ELLI: 57.75 (+0.69), SILC: 44.20 (+1.71), SGMO: 14.70 (-0.84), AFFX: 12.44 (-0.16), BABY: 42.15 (-0.01), HBIO: 6.22 (+0.08), EXAM: 43.13 (-0.04), IART: 61.31 (+0.84), SNCR: 51.48 (-0.44), CNMD: 53.40 (-0.83), BJRI: 49.52 (-3.92), NLNK: 52.10 (-0.90), CTRN: 24.69 (+0.29), ANAC: 64.49 (-2.10), PRSC: 49.35 (+0.02), RRGB: 83.32 (+1.41), ALOG: 88.06 (-0.13), DIOD: 27.28 (-0.72), LGND: 89.75 (+0.83), DEPO: 27.65 (+0.36), ASTE: 43.09 (+0.01), DYAX: 27.44 (-0.85), FARO: 43.44 (-1.22), ECOL: 49.43 (+0.31), PFPT: 54.33 (-2.60), MTSI: 31.41 (-1.92), IRWD: 15.10 (-0.38), ABAX: 63.62 (+0.31), ANIP: 70.26 (-1.52), FORM: 9.16 (-0.13), QLGC: 15.26 (+0.07), ADUS: 28.86 (+0.41), SNHY: 41.42 (+0.11), EBIX: 29.77 (-0.21), SWHC: 15.01 (+0.10)

Harvard Bioscience Up 24.5% Since SmarTrend Uptrend Call (HBIO)
Comtex SmarTrend(R) - Thu Apr 02, 10:02AM CDT
SmarTrend identified an Uptrend for Harvard Bioscience (NASDAQ:HBIO) on October 21st, 2014 at $4.69. In approximately 5 months, Harvard Bioscience has returned 24.52% as of today's recent price of $5.84.
HBIO: 6.22 (+0.08)

Uptrend Call Working As Harvard Bioscience Stock Rises 15.8% (HBIO)
Comtex SmarTrend(R) - Wed Mar 25, 5:10PM CDT
SmarTrend identified an Uptrend for Harvard Bioscience (NASDAQ:HBIO) on October 21st, 2014 at $4.69. In approximately 5 months, Harvard Bioscience has returned 15.78% as of today's recent price of $5.43.
HBIO: 6.22 (+0.08)

Leading 100 Medical Devices Companies of USA/Canada 2015
M2 - Mon Mar 23, 10:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9k2tjj/usacanada) has announced the addition of the "USA/Canada Medical Devices 100: An Industry Report" report to their offering. The United States is the largest medical device market in the world with a market size of around $110 billion, and it is expected to reach $133 billion by 2016 The U.S. market value represented about 38 percent of the global medical device market in 2012. The U.S. medical device companies are highly regarded globally for their innovations and high technology products. Canada's medical device market ranks as the ninth largest in the world. Canada has an estimated around $7 billion medical device market accounting for about 2 percent of the global market. The market is projected to increase at a CAGR of 4.0% to reach US$8.3bn by 2018. Around 80% of the market is supplied by imports, principally from the USA. With this special industry report, our endeavor is to provide the new investors with a complete resourceful research report for familiarizing with the present investment trends in USA/Canadian medical devices industry, which they would find beneficial to pursue for making business decisions in this sector. Report Highlights: - Leading 100 medical devices companies of USA/Canada - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances with foreign companies - International presence of USA/Canadian medical devices companies - R&D activities in the industry Report Includes Companies Engaged in: - Manufacturing medical equipments/devices that have life span of more than one year and that can be used repeatedly on multiple patients or multiple medical tests can be done by using them - Manufacturing medical devices providing any medical activity and/or treatment - Manufacturing diagnostic devices - Manufacturing high-tech medical instruments - Manufacturing life-support medical devices Key Features: - Financial information compiled from reliable primary and secondary sources - Business news and transactions compiled from primary news sources, company websites, and press releases - Original news source links provided for each news for further reference - Senior colleagues who analyze news have years of experience Companies Mentioned (Partial List) - Harvard Bioscience, Inc. (United States) - Hasco Medical, Incorporation (United States) - Heartware International Inc (United States) - HEI Inc (United States) - Hill-Rom Holdings, Incorporation (United States) - Hologic, Inc. (United States) - IDEXX Laboratories Inc (United States) - Illumina, Inc. (United States) - Imris Incorporation (Canada) - Inogen Inc (United States) - Insulet Corporation (United States) - Integra LifeSciences Holdings Corporation (United States) - Invacare Corporation (United States) - IRIDEX Corporation (United States) - Lifeline Scientific, Inc (United States) - Lifeloc Technologies Inc (United States) - Medifocus Inc (Canada) For more information visit http://www.researchandmarkets.com/research/9k2tjj/usacanada
IRIX: 10.02 (+0.19), ILMN: 189.59 (-3.01), HBIO: 6.22 (+0.08), PODD: 30.72 (+0.11), IART: 61.31 (+0.84), IVC: 20.68 (+0.14), IMRS: 0.69 (+0.04), INGN: 37.13 (+0.11), IDXX: 164.05 (+4.65), HRC: 51.94 (+0.03), HOLX: 33.99 (+0.57)

The Best Small Cap Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Sat Mar 21, 11:24PM CDT

DMND: 29.91 (-0.42), PMC: 30.50 (-0.29), MATW: 50.80 (-0.20), ELLI: 57.75 (+0.69), WWE: 14.48 (-0.18), SILC: 44.20 (+1.71), SGMO: 14.70 (-0.84), TRNX: 26.25 (+0.01), OFIX: 36.46 (+0.10), AFFX: 12.44 (-0.16), CHE: 123.62 (+0.08), BABY: 42.15 (-0.01), HBIO: 6.22 (+0.08), IART: 61.31 (+0.84), SONC: 30.83 (-0.21), SNCR: 51.48 (-0.44), CNMD: 53.40 (-0.83), BJRI: 49.52 (-3.92), NLNK: 52.10 (-0.90), ANAC: 64.49 (-2.10), XSD: 85.14 (-2.91), PRSC: 49.35 (+0.02), RRGB: 83.32 (+1.41), IPAR: 31.75 (-0.88), ALOG: 88.06 (-0.13), DIOD: 27.28 (-0.72), NSIT: 28.68 (+0.01), LGND: 89.75 (+0.83), DEPO: 27.65 (+0.36), ASTE: 43.09 (+0.01), DYAX: 27.44 (-0.85), ECOL: 49.43 (+0.31), PFPT: 54.33 (-2.60), MTSI: 31.41 (-1.92), IRWD: 15.10 (-0.38), ABAX: 63.62 (+0.31), FLDM: 42.47 (-0.73), SCSS: 34.50 (+0.86), ANIP: 70.26 (-1.52), FORM: 9.16 (-0.13), BEAT: 8.60 (-0.26), QLGC: 15.26 (+0.07), ADUS: 28.86 (+0.41), PENX: 18.98 (+0.14), EBIX: 29.77 (-0.21), CORT: 6.32 (-0.12), SWHC: 15.01 (+0.10), OCFC: 17.32 (+0.42)

11.7% Return Seen to Date on SmarTrend Harvard Bioscience Call (HBIO)
Comtex SmarTrend(R) - Wed Mar 18, 11:41AM CDT
SmarTrend identified an Uptrend for Harvard Bioscience (NASDAQ:HBIO) on October 21st, 2014 at $4.69. In approximately 5 months, Harvard Bioscience has returned 11.73% as of today's recent price of $5.24.
HBIO: 6.22 (+0.08)

Harvard Bioscience' (HBIO) CEO Jeffrey Duchemin on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 26, 2:41PM CST

HBIO: 6.22 (+0.08)

Harvard Bioscience posts 4Q loss
Automated Insights - Thu Feb 26, 10:48AM CST
HOLLISTON, Mass. (AP) _ Harvard Bioscience Inc. (HBIO) on Thursday reported a loss of $19,000 in its fourth quarter.
HBIO: 6.22 (+0.08)

Harvard Bioscience (HBIO) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Feb 26, 9:55AM CST

HBIO: 6.22 (+0.08)

Harvard Bioscience beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 6:33AM CST

HBIO: 6.22 (+0.08)

The Top Small Cap Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Sun Feb 22, 2:51AM CST

MATW: 50.80 (-0.20), RTIX: 5.86 (+0.09), ELLI: 57.75 (+0.69), KFRC: 22.07 (+0.04), SILC: 44.20 (+1.71), SGMO: 14.70 (-0.84), AFFX: 12.44 (-0.16), BABY: 42.15 (-0.01), HBIO: 6.22 (+0.08), EXAM: 43.13 (-0.04), IART: 61.31 (+0.84), UEIC: 57.15 (-0.85), CNMD: 53.40 (-0.83), BJRI: 49.52 (-3.92), NLNK: 52.10 (-0.90), CTRN: 24.69 (+0.29), ANAC: 64.49 (-2.10), CSU: 26.68 (+0.11), RRGB: 83.32 (+1.41), DIOD: 27.28 (-0.72), DEPO: 27.65 (+0.36), DYAX: 27.44 (-0.85), FARO: 43.44 (-1.22), PERY: 24.80 (-0.16), PACB: 5.76 (-0.14), PFPT: 54.33 (-2.60), MTSI: 31.41 (-1.92), IRWD: 15.10 (-0.38), ABAX: 63.62 (+0.31), SCSS: 34.50 (+0.86), ANIP: 70.26 (-1.52), FORM: 9.16 (-0.13), BEAT: 8.60 (-0.26), QLGC: 15.26 (+0.07), PENX: 18.98 (+0.14), EBIX: 29.77 (-0.21), CORT: 6.32 (-0.12), UTMD: 57.20 (unch), DAVE: 30.32 (+0.36), SWHC: 15.01 (+0.10)

Next Week In Biotech: Arena And Vivus Report, Radiesse And Avedro Ad Comms
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
LXRX: 1.10 (+0.03), AMRN: 2.33 (-0.10), HWAY: 17.61 (-1.89), HLS: 46.76 (+0.05), CYBX: 62.89 (-0.30), ESRX: 87.34 (+0.45), ECYT: 6.17 (-0.13), DXCM: 69.43 (-1.13), NSTG: 12.11 (-0.09), SRPT: 13.42 (-0.24), HZNP: 31.75 (+0.97), MDXG: 9.81 (-0.39), DEPO: 27.65 (+0.36), ANIK: 38.35 (-0.32), NKTR: 10.77 (-0.29), KERX: 11.41 (-0.32), ALIM: 4.94 (-0.07), EPZM: 20.21 (+0.16), AEGR: 25.42 (-0.52), MDRX: 12.59 (-0.15), ELGX: 17.08 (-0.02), NUVA: 43.99 (+0.23), HPTX: 45.97 (-0.11), GNMK: 10.69 (-0.24), MDVN: 131.01 (-1.50), HBIO: 6.22 (+0.08), ACAD: 38.36 (-0.54), ST: 58.00 (-0.29), RPTP: 10.81 (+0.10), FMI: 46.57 (-2.16), GMED: 24.79 (+0.15), JAZZ: 189.42 (+0.33), PTCT: 70.48 (-0.88), INFI: 14.54 (-0.11), ARNA: 4.49 (+0.05), EXEL: 3.08 (-0.02), NEO: 4.75 (-0.11), EXAS: 21.98 (-1.08), ALKS: 62.26 (-1.19), HTWR: 78.80 (-0.82), MNKD: 4.80 (-0.16), IPXL: 49.55 (-0.53), SQNM: 4.52 (-0.10), HALO: 16.86 (-0.08), ISIS: 66.37 (-1.38), CLVS: 92.03 (+1.78), BIO: 137.41 (+0.01), BIOS: 5.26 (+0.01), PCRX: 85.07 (+0.80)

Harvard Bioscience Appoints Ryan Atienza to Vice President of Sales at Its Denville Scientific Subsidiary
GlobeNewswire - Wed Feb 18, 6:06AM CST
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of equipment, instruments and solutions to advance life science, has appointed Ryan Atienza to Vice President of Sales, a newly created position, at its Denville Scientific subsidiary, effective February 16. Mr. Atienza will be a member of the executive leadership team responsible for North American sales.
HBIO: 6.22 (+0.08), BDX: 144.33 (-0.02), AXP: 77.99 (-0.16)

Harvard Bioscience Shares Up 13.4% Since SmarTrend's Buy Recommendation (HBIO)
Comtex SmarTrend(R) - Tue Feb 17, 5:13PM CST
SmarTrend identified an Uptrend for Harvard Bioscience (NASDAQ:HBIO) on October 21st, 2014 at $4.69. In approximately 4 months, Harvard Bioscience has returned 13.43% as of today's recent price of $5.32.
HBIO: 6.22 (+0.08)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 8

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 11

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 19

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 9

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 17

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 12

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 19

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading

Top 5 Most Recently Viewed Articles

Middlefield Real Estate ETF Plans for Q4 Distributions

Updated Category News Views 155

Middlefield Real Estate Dividend ETF Announces Fourth Quarter Distributions Middlefield Real Estate Dividend ETF (TSX:MREL) has recently shared exciting news regarding its distributions for the fourth quarter. This announcement holds significance for unitholders as it outlines the upcoming distribution schedule, providing clarity and insight into the Fund's commitment to...

Continue Reading
PARRIS Law Firm Achieves Historic Verdicts Exceeding $100M

Updated Category News Views 203

PARRIS Law Firm Achieves Remarkable Legal Success In an extraordinary demonstration of legal expertise, PARRIS Law Firm has amassed over $100 million in jury verdicts through three significant personal injury cases, all completed in just eight days. Each verdict exceeded $30 million, showcasing the firm’s dedication to securing justice for their clients. Exceptional...

Continue Reading
Elemental Altus and EMX Merger Solidifies Future Growth Potential

Updated Category News Views 165

Overview of the Merger Elemental Altus Royalties Corp. (TSXV: ELE) has successfully completed its merger with EMX Royalty Corporation (NYSE: EMX). This merger, executed through a statutory plan of arrangement under the Business Corporations Act, is designed to leverage both companies' strengths and position them for future success. Name Change and Trading Updates As part...

Continue Reading
Flow Control Management Welcomes Aquatrol into Its Family

Updated Category News Views 312

Flow Control Management Expands Its Portfolio with Aquatrol Inc. Flow Control Management (FCM), recognized as a private equity-backed holding company, has successfully added Aquatrol Inc. to its diverse portfolio. This acquisition brings a significant boost to FCM's range of safety and pressure relief valves. As an established player in the flow control sector, FCM aims...

Continue Reading
Childcare Management Software Market Growth Insights

Updated Category News Views 88

Growth Projections for Childcare Management Software Market The global childcare management software market is on a remarkable growth path, with projections estimating it will reach $416.7 million. Recently, the market was valued at around $190.3 million, indicating a strong upward trend with a compound annual growth rate (CAGR) of 8.9% expected from 2024 to 2032. This...

Continue Reading